{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T11:48:41Z","timestamp":1778586521170,"version":"3.51.4"},"reference-count":64,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","surgpath.theclinics.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgical Pathology Clinics"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.path.2016.04.004","type":"journal-article","created":{"date-parts":[[2016,8,11]],"date-time":"2016-08-11T21:52:15Z","timestamp":1470952335000},"page":"391-404","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["The Emerging Molecular Landscape of Urothelial Carcinoma"],"prefix":"10.1016","volume":"9","author":[{"given":"James P.","family":"Solomon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donna E.","family":"Hansel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.path.2016.04.004_bib1","unstructured":"American Cancer Society. Cancer facts and figures: 2015. Atlanta (GA): American cancer society; 2015."},{"key":"10.1016\/j.path.2016.04.004_bib2","series-title":"The urinary tract: a comprehensive guide to patient diagnosis and management","first-page":"83","article-title":"Bladder cancer overview and staging","author":"Morgan","year":"2012"},{"key":"10.1016\/j.path.2016.04.004_bib3","series-title":"Bladder cancer: second international consultation on bladder cancer \u2013 Vienna","year":"2012"},{"issue":"6","key":"10.1016\/j.path.2016.04.004_bib4","doi-asserted-by":"crossref","first-page":"E672","DOI":"10.1073\/pnas.1313580111","article-title":"Whole-genome sequencing identifies genomic heterogeneity at a nucleotide and chromosomal level in bladder cancer","volume":"111","author":"Morrison","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"10.1016\/j.path.2016.04.004_bib5","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1158\/1078-0432.CCR-10-2770","article-title":"New strategies in muscle-invasive bladder cancer: on the road to personalized medicine","volume":"17","author":"Shah","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.path.2016.04.004_bib6","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/nrc1697","article-title":"Urothelial tumorigenesis: a tale of divergent pathways","volume":"5","author":"Wu","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.path.2016.04.004_bib7","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature12965","article-title":"Comprehensive molecular characterization of urothelial bladder carcinoma","volume":"507","author":"Cancer Genome Atlas Research Network","year":"2014","journal-title":"Nature"},{"issue":"22","key":"10.1016\/j.path.2016.04.004_bib8","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1038\/sj.onc.1210421","article-title":"MAP kinase signalling pathways in cancer","volume":"26","author":"Dhillon","year":"2007","journal-title":"Oncogene"},{"issue":"7","key":"10.1016\/j.path.2016.04.004_bib9","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/mc.22125","article-title":"PIK3CA gene alterations in bladder cancer are frequent and associate with reduced recurrence in non-muscle invasive tumors","volume":"54","author":"Due\u00f1as","year":"2015","journal-title":"Mol Carcinog"},{"issue":"5","key":"10.1016\/j.path.2016.04.004_bib10","first-page":"2312","article-title":"Activation of RAS family genes in urothelial carcinoma","volume":"181","author":"Boulalas","year":"2009","journal-title":"J\u00a0Urol"},{"issue":"5888","key":"10.1016\/j.path.2016.04.004_bib11","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/300149a0","article-title":"A\u00a0point mutation is responsible for the acquisition of transforming properties by the T24 human bladder-carcinoma oncogene","volume":"300","author":"Reddy","year":"1982","journal-title":"Nature"},{"issue":"5888","key":"10.1016\/j.path.2016.04.004_bib12","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/300143a0","article-title":"Mechanism of activation of a human oncogene","volume":"300","author":"Tabin","year":"1982","journal-title":"Nature"},{"issue":"16","key":"10.1016\/j.path.2016.04.004_bib13","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1038\/sj.onc.1204315","article-title":"Role of Ha-ras activation in superficial papillary pathway of urothelial tumor formation","volume":"20","author":"Zhang","year":"2001","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.path.2016.04.004_bib14","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nrc2780","article-title":"Fibroblast growth factor signalling: from development to cancer","volume":"10","author":"Turner","year":"2010","journal-title":"Nat Rev Cancer"},{"issue":"22","key":"10.1016\/j.path.2016.04.004_bib15","doi-asserted-by":"crossref","first-page":"10441","DOI":"10.1158\/0008-5472.CAN-05-1718","article-title":"Alternative splicing of fibroblast growth factor receptor 3 produces a secreted isoform that inhibits fibroblast growth factor-induced proliferation and is repressed in urothelial carcinoma cell lines","volume":"65","author":"Tomlinson","year":"2005","journal-title":"Cancer Res"},{"issue":"33","key":"10.1016\/j.path.2016.04.004_bib16","doi-asserted-by":"crossref","first-page":"5218","DOI":"10.1038\/sj.onc.1208705","article-title":"FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma","volume":"24","author":"Jebar","year":"2005","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.path.2016.04.004_bib17","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/path.2207","article-title":"FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer","volume":"213","author":"Tomlinson","year":"2007","journal-title":"J\u00a0Pathol"},{"issue":"21","key":"10.1016\/j.path.2016.04.004_bib18","doi-asserted-by":"crossref","first-page":"8472","DOI":"10.1158\/0008-5472.CAN-09-0744","article-title":"Distinct microRNA alterations characterize high- and low-grade bladder cancer","volume":"69","author":"Catto","year":"2009","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.path.2016.04.004_bib19","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1093\/hmg\/dds486","article-title":"Oncogenic FGFR3 gene fusions in bladder cancer","volume":"22","author":"Williams","year":"2013","journal-title":"Hum Mol Genet"},{"issue":"9","key":"10.1016\/j.path.2016.04.004_bib20","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/j.1442-2042.2011.02809.x","article-title":"Immunohistochemical biomarkers for bladder cancer prognosis","volume":"18","author":"Matsushita","year":"2011","journal-title":"Int J Urol"},{"issue":"6","key":"10.1016\/j.path.2016.04.004_bib21","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1038\/onc.2012.87","article-title":"PIK3CA mutation spectrum in urothelial carcinoma reflects cell context-dependent signaling and phenotypic outputs","volume":"32","author":"Ross","year":"2013","journal-title":"Oncogene"},{"issue":"19","key":"10.1016\/j.path.2016.04.004_bib22","doi-asserted-by":"crossref","first-page":"6008","DOI":"10.1158\/1078-0432.CCR-09-0898","article-title":"Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer","volume":"15","author":"Platt","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"15","key":"10.1016\/j.path.2016.04.004_bib23","doi-asserted-by":"crossref","first-page":"7401","DOI":"10.1158\/0008-5472.CAN-06-1182","article-title":"PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors","volume":"66","author":"Lopez-Knowles","year":"2006","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.path.2016.04.004_bib24","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1053\/j.seminoncol.2012.08.008","article-title":"Prognostic value of cell-cycle regulation biomarkers in bladder cancer","volume":"39","author":"Mitra","year":"2012","journal-title":"Semin Oncol"},{"issue":"1","key":"10.1016\/j.path.2016.04.004_bib25","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/00019606-199300020-00002","article-title":"Molecular-genetic alterations of chromosome 17 and p53 nuclear overexpression in human bladder cancer","volume":"2","author":"Dalbagni","year":"1993","journal-title":"Diagn Mol Pathol"},{"issue":"19","key":"10.1016\/j.path.2016.04.004_bib26","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1056\/NEJM199411103311903","article-title":"Accumulation of nuclear p53 and tumor progression in bladder cancer","volume":"331","author":"Esrig","year":"1994","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.path.2016.04.004_bib27","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/jnci\/85.1.53","article-title":"Nuclear overexpression of p53-protein in transitional cell bladder carcinoma: a marker for disease progression","volume":"85","author":"Sarkis","year":"1993","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.path.2016.04.004_bib28","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/bjc.1995.41","article-title":"p53 immunohistochemistry as an independent prognostic factor for superficial transitional-cell carcinoma of the bladder","volume":"71","author":"Serth","year":"1995","journal-title":"Br J Cancer"},{"issue":"34","key":"10.1016\/j.path.2016.04.004_bib29","doi-asserted-by":"crossref","first-page":"5352","DOI":"10.1200\/JCO.2006.10.4125","article-title":"p53 gene and protein status: the role of p53 alterations in predicting outcome in patients with bladder cancer","volume":"25","author":"George","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"6584","key":"10.1016\/j.path.2016.04.004_bib30","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/381713a0","article-title":"Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21","volume":"381","author":"Waldman","year":"1996","journal-title":"Nature"},{"issue":"25","key":"10.1016\/j.path.2016.04.004_bib31","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1200\/JCO.2010.34.4028","article-title":"Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status","volume":"29","author":"Stadler","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"16","key":"10.1016\/j.path.2016.04.004_bib32","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1038\/sj.onc.1205304","article-title":"Amplification pattern of 12q13-q15 genes (MDM2, CDK4, GLI) in urinary bladder cancer","volume":"21","author":"Simon","year":"2002","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.path.2016.04.004_bib33","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/path.4017","article-title":"CDKN2A homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial bladder carcinoma","volume":"227","author":"Rebouissou","year":"2012","journal-title":"J\u00a0Pathol"},{"issue":"12","key":"10.1016\/j.path.2016.04.004_bib34","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/j.humpath.2006.05.017","article-title":"Correlation of cyclin D1 and E1 expression with bladder cancer presence, invasion, progression, and metastasis","volume":"37","author":"Shariat","year":"2006","journal-title":"Hum Pathol"},{"issue":"9","key":"10.1016\/j.path.2016.04.004_bib35","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.1158\/0008-5472.CAN-09-4213","article-title":"Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome","volume":"70","author":"Lindgren","year":"2010","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.path.2016.04.004_bib36","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrc3817","article-title":"Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity","volume":"15","author":"Knowles","year":"2015","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"10.1016\/j.path.2016.04.004_bib37","doi-asserted-by":"crossref","first-page":"372","DOI":"10.5858\/arpa.2011-0471-RA","article-title":"Emerging critical role of molecular testing in diagnostic genitourinary pathology","volume":"136","author":"Netto","year":"2012","journal-title":"Arch Pathol Lab Med"},{"issue":"22","key":"10.1016\/j.path.2016.04.004_bib38","first-page":"7652","article-title":"Mutation spectrum of the 9q34 tuberous sclerosis gene TSC1 in transitional cell carcinoma of the bladder","volume":"63","author":"Knowles","year":"2003","journal-title":"Cancer Res"},{"issue":"16","key":"10.1016\/j.path.2016.04.004_bib39","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1038\/sj.onc.1202854","article-title":"Mutation of the 9q34 gene TSC1 in sporadic bladder cancer","volume":"18","author":"Hornigold","year":"1999","journal-title":"Oncogene"},{"issue":"12","key":"10.1016\/j.path.2016.04.004_bib40","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1158\/1078-0432.CCR-12-0077-T","article-title":"A\u00a0molecular taxonomy for urothelial carcinoma","volume":"18","author":"Sjodahl","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.path.2016.04.004_bib41","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.ajpath.2013.05.013","article-title":"Toward a molecular pathologic classification of urothelial carcinoma","volume":"183","author":"Sjodahl","year":"2013","journal-title":"Am J Pathol"},{"issue":"8","key":"10.1016\/j.path.2016.04.004_bib42","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1073\/pnas.1318376111","article-title":"Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology","volume":"111","author":"Damrauer","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.path.2016.04.004_bib43","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","article-title":"Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy","volume":"25","author":"Choi","year":"2014","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.path.2016.04.004_bib44","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13073-015-0144-4","article-title":"Integrative epigenomic analysis of differential DNA methylation in urothelial carcinoma","volume":"7","author":"Aine","year":"2015","journal-title":"Genome Med"},{"issue":"10","key":"10.1016\/j.path.2016.04.004_bib45","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1200\/JCO.2011.38.6979","article-title":"Randomized phase III study comparing paclitaxel\/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987","volume":"30","author":"Bellmunt","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.path.2016.04.004_bib46","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ctrv.2015.03.004","article-title":"Molecular biology and targeted therapies for urothelial carcinoma","volume":"41","author":"Seront","year":"2015","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"10.1016\/j.path.2016.04.004_bib47","article-title":"Final\u00a0results of a multicenter, open-label phase II trial of dovitinib (TKI258) in patients with advanced urothelial carcinoma with either mutated or nonmutated FGFR3","volume":"31","author":"Milowsky","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"6104","key":"10.1016\/j.path.2016.04.004_bib48","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1126\/science.1226344","article-title":"Genome sequencing identifies a basis for everolimus sensitivity","volume":"338","author":"Iyer","year":"2012","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.path.2016.04.004_bib49","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/j.1464-410X.2012.11720.x","article-title":"Phase II study of everolimus in metastatic urothelial cancer","volume":"112","author":"Milowsky","year":"2013","journal-title":"BJU Int"},{"issue":"6","key":"10.1016\/j.path.2016.04.004_bib50","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1093\/annonc\/mdn749","article-title":"A\u00a0phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102","volume":"20","author":"Philips","year":"2009","journal-title":"Ann Oncol"},{"issue":"28","key":"10.1016\/j.path.2016.04.004_bib51","doi-asserted-by":"crossref","first-page":"3545","DOI":"10.1200\/JCO.2012.41.9572","article-title":"Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma","volume":"30","author":"Wong","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"16","key":"10.1016\/j.path.2016.04.004_bib52","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1200\/JCO.2006.08.0994","article-title":"Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2\/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial","volume":"25","author":"Hussain","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.path.2016.04.004_bib53","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1200\/JCO.2012.42.5215","article-title":"Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer","volume":"31","author":"Balar","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.path.2016.04.004_bib54","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/ng.2798","article-title":"Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation","volume":"45","author":"Guo","year":"2013","journal-title":"Nat Genet"},{"issue":"25","key":"10.1016\/j.path.2016.04.004_bib55","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1200\/JCO.2012.46.5740","article-title":"Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer","volume":"31","author":"Iyer","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.path.2016.04.004_bib56","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.eururo.2014.06.050","article-title":"Genomic predictors of survival in patients with high-grade urothelial carcinoma of the bladder","volume":"67","author":"Kim","year":"2015","journal-title":"Eur Urol"},{"issue":"269","key":"10.1016\/j.path.2016.04.004_bib57","doi-asserted-by":"crossref","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci Signal"},{"issue":"5","key":"10.1016\/j.path.2016.04.004_bib58","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.path.2016.04.004_bib59","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2478\/raon-2014-0015","article-title":"EGFR-expression in primary urinary bladder cancer and corresponding metastases and the relation to HER2-expression. On the possibility to target these receptors with radionuclides","volume":"49","author":"Carlsson","year":"2015","journal-title":"Radiol Oncol"},{"issue":"3","key":"10.1016\/j.path.2016.04.004_bib60","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s11523-014-0341-x","article-title":"Comparison of tyrosine kinase receptors HER2, EGFR, and VEGFR expression in micropapillary urothelial carcinoma with invasive urothelial carcinoma","volume":"10","author":"Li","year":"2015","journal-title":"Target Oncol"},{"issue":"2","key":"10.1016\/j.path.2016.04.004_bib61","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1136\/jclinpath-2012-200944","article-title":"Her2 amplification distinguishes a subset of non-muscle-invasive bladder cancers with a high risk of progression","volume":"66","author":"Chen","year":"2013","journal-title":"J\u00a0Clin Pathol"},{"issue":"1","key":"10.1016\/j.path.2016.04.004_bib62","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1158\/1078-0432.CCR-13-1992","article-title":"A\u00a0high frequency of activating extracellular domain ERBB2 (HER2) mutation in micropapillary urothelial carcinoma","volume":"20","author":"Ross","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.path.2016.04.004_bib63","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1038\/modpathol.2011.69","article-title":"HER2 gene amplification occurs frequently in the micropapillary variant of urothelial carcinoma: analysis by dual-color in situ hybridization","volume":"24","author":"Ching","year":"2011","journal-title":"Mod Pathol"},{"issue":"2","key":"10.1016\/j.path.2016.04.004_bib64","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1309\/41VLTFX3YPP1HF6F","article-title":"HER2 overexpression and amplification in urothelial carcinoma of the bladder is associated with MYC coamplification in a subset of cases","volume":"130","author":"Hansel","year":"2008","journal-title":"Am J Clin Pathol"}],"container-title":["Surgical Pathology Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875918116300174?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875918116300174?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T21:00:40Z","timestamp":1718744440000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1875918116300174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":64,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["S1875918116300174"],"URL":"https:\/\/doi.org\/10.1016\/j.path.2016.04.004","relation":{},"ISSN":["1875-9181"],"issn-type":[{"value":"1875-9181","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Emerging Molecular Landscape of Urothelial Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Surgical Pathology Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.path.2016.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}